CA2769991C - Met inhibitors for enhancing radiotherapy efficacy - Google Patents
Met inhibitors for enhancing radiotherapy efficacy Download PDFInfo
- Publication number
- CA2769991C CA2769991C CA2769991A CA2769991A CA2769991C CA 2769991 C CA2769991 C CA 2769991C CA 2769991 A CA2769991 A CA 2769991A CA 2769991 A CA2769991 A CA 2769991A CA 2769991 C CA2769991 C CA 2769991C
- Authority
- CA
- Canada
- Prior art keywords
- met
- met inhibitor
- radiotherapy
- polynucleotide
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158861.2 | 2011-03-18 | ||
| EP11158861.2A EP2500036B1 (en) | 2011-03-18 | 2011-03-18 | MET inhibitors for enhancing radiotherapy efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2769991A1 CA2769991A1 (en) | 2012-09-18 |
| CA2769991C true CA2769991C (en) | 2018-05-15 |
Family
ID=44260211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2769991A Active CA2769991C (en) | 2011-03-18 | 2012-03-01 | Met inhibitors for enhancing radiotherapy efficacy |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20120237524A1 (show.php) |
| EP (1) | EP2500036B1 (show.php) |
| JP (1) | JP5671487B2 (show.php) |
| KR (1) | KR101540838B1 (show.php) |
| CN (1) | CN102688491A (show.php) |
| AU (1) | AU2012201303B2 (show.php) |
| BR (1) | BR102012006063B1 (show.php) |
| CA (1) | CA2769991C (show.php) |
| CY (1) | CY1115374T1 (show.php) |
| DK (1) | DK2500036T3 (show.php) |
| EA (1) | EA028590B1 (show.php) |
| ES (1) | ES2489475T3 (show.php) |
| HR (1) | HRP20140729T1 (show.php) |
| IL (1) | IL218293A (show.php) |
| MX (1) | MX2012003084A (show.php) |
| PL (1) | PL2500036T3 (show.php) |
| PT (1) | PT2500036E (show.php) |
| RS (1) | RS53468B (show.php) |
| SG (1) | SG184637A1 (show.php) |
| SI (1) | SI2500036T1 (show.php) |
| SM (1) | SMT201400106B (show.php) |
| ZA (1) | ZA201201992B (show.php) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| CN110320365B (zh) * | 2019-07-06 | 2022-07-22 | 湖南莱拓福生物科技有限公司 | NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒 |
| CN121015920A (zh) | 2019-09-16 | 2025-11-28 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| EP1592713A2 (en) * | 2003-02-13 | 2005-11-09 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| BRPI0412885A (pt) * | 2003-07-18 | 2006-10-03 | Amgen Inc | polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf) |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| PT1981981E (pt) * | 2006-02-06 | 2011-10-04 | Metheresis Translational Res Sa | Anticorpos monoclonais anti-met, fragmentos e vectores destes, para o tratamento de tumores e produtos correspondentes |
| EP2019116A1 (en) * | 2007-07-26 | 2009-01-28 | Helmholtz-Zentrum für Infektionsforschung GmbH | Inhibitor of the met-receptor and its use |
-
2011
- 2011-03-18 RS RS20140404A patent/RS53468B/sr unknown
- 2011-03-18 DK DK11158861.2T patent/DK2500036T3/da active
- 2011-03-18 EP EP11158861.2A patent/EP2500036B1/en active Active
- 2011-03-18 SI SI201130217T patent/SI2500036T1/sl unknown
- 2011-03-18 PL PL11158861T patent/PL2500036T3/pl unknown
- 2011-03-18 PT PT111588612T patent/PT2500036E/pt unknown
- 2011-03-18 ES ES11158861.2T patent/ES2489475T3/es active Active
-
2012
- 2012-02-22 SG SG2012012514A patent/SG184637A1/en unknown
- 2012-02-23 IL IL218293A patent/IL218293A/en active IP Right Grant
- 2012-02-24 JP JP2012039193A patent/JP5671487B2/ja active Active
- 2012-03-01 CA CA2769991A patent/CA2769991C/en active Active
- 2012-03-02 AU AU2012201303A patent/AU2012201303B2/en active Active
- 2012-03-13 MX MX2012003084A patent/MX2012003084A/es active IP Right Grant
- 2012-03-13 KR KR1020120025311A patent/KR101540838B1/ko active Active
- 2012-03-16 BR BR102012006063-9A patent/BR102012006063B1/pt active IP Right Grant
- 2012-03-16 CN CN2012100803665A patent/CN102688491A/zh active Pending
- 2012-03-16 ZA ZA2012/01992A patent/ZA201201992B/en unknown
- 2012-03-16 EA EA201200329A patent/EA028590B1/ru not_active IP Right Cessation
- 2012-03-19 US US13/423,830 patent/US20120237524A1/en not_active Abandoned
-
2014
- 2014-07-24 CY CY20141100561T patent/CY1115374T1/el unknown
- 2014-07-29 HR HRP20140729AT patent/HRP20140729T1/hr unknown
- 2014-07-31 SM SM201400106T patent/SMT201400106B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012003084A (es) | 2012-09-17 |
| EA028590B1 (ru) | 2017-12-29 |
| SMT201400106B (it) | 2014-11-10 |
| HRP20140729T1 (hr) | 2014-08-29 |
| CN102688491A (zh) | 2012-09-26 |
| JP5671487B2 (ja) | 2015-02-18 |
| AU2012201303B2 (en) | 2013-11-07 |
| KR20120106582A (ko) | 2012-09-26 |
| ES2489475T3 (es) | 2014-09-02 |
| BR102012006063B1 (pt) | 2023-03-07 |
| BR102012006063A2 (pt) | 2021-11-16 |
| EP2500036A1 (en) | 2012-09-19 |
| EA201200329A3 (ru) | 2013-01-30 |
| SI2500036T1 (sl) | 2014-09-30 |
| SG184637A1 (en) | 2012-10-30 |
| BR102012006063A8 (pt) | 2022-11-08 |
| IL218293A (en) | 2016-06-30 |
| AU2012201303A1 (en) | 2012-10-04 |
| KR101540838B1 (ko) | 2015-08-06 |
| CA2769991A1 (en) | 2012-09-18 |
| HK1174539A1 (en) | 2013-06-14 |
| EA201200329A2 (ru) | 2012-09-28 |
| PL2500036T3 (pl) | 2014-10-31 |
| US20120237524A1 (en) | 2012-09-20 |
| CY1115374T1 (el) | 2017-01-04 |
| RS53468B (sr) | 2014-12-31 |
| IL218293A0 (en) | 2012-07-31 |
| EP2500036B1 (en) | 2014-05-07 |
| PT2500036E (pt) | 2014-08-25 |
| ZA201201992B (en) | 2015-05-27 |
| JP2012196206A (ja) | 2012-10-18 |
| DK2500036T3 (da) | 2014-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2769991C (en) | Met inhibitors for enhancing radiotherapy efficacy | |
| Holz et al. | Epithelial–mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells | |
| CA2736929C (en) | Inhibition of plgf to treat philadelphia chromosome positive leukemia | |
| US20230227823A1 (en) | Fmrp and cancer treatment | |
| Guo et al. | FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1 | |
| CN112543809A (zh) | 包含C/EBPα saRNA的组合疗法 | |
| Crose et al. | Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma | |
| US11679100B2 (en) | Methods of enhancing immunity | |
| HK1174539B (en) | Met inhibitors for enhancing radiotherapy efficacy | |
| US20140056910A1 (en) | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug | |
| Mongiardi et al. | Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing. Cancers 2021, 13, 484 | |
| Jaunecker | The role of FGFR4 activity on proliferation, differentiation and downstream signaling in glioma | |
| Kazimova et al. | Identification of Biologically Active Factors in the Ionizing Radiation Regulated Secretome | |
| Rosa | Doctorate Program in Molecular Oncology and Endocrinology Doctorate School in Molecular Medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| EEER | Examination request |
Effective date: 20121224 |